News & Events

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million…

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 11, 2026, Steve O’Loughlin tendered his resignation as the Chief Financial Officer of Actinium Pharmaceuticals, Inc. (the “ Company ”), effective as of February 27, 2026, to pursue other opportunities (the “ Effective Date ”). There were no disagreements with the Company that contributed to Mr. O’Loughlin’s resignation. Additionally, on February 13, 2026, to fill the executive v…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Class III Directors On November 26, 2025, Actinium Pharmaceuticals, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). As previously reported in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 5, 2025 (the “Proxy Statement”), the term of each o…

Changes in Registrant's Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm Based on information provided by Marcum LLP (“ Marcum ”), on November 1, 2024, CBIZ CPAs P.C. (“ CBIZ CPAs ”) acquired the attest business of Marcum. On May 08, 2025, Actinium Pharmaceuticals, Inc. (the “ Company ”) dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition. The audit report of Marcum on the Company’s consolidated…